Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism

Abstract Background The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have highlighted that diazoxide has seri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2020-12, Vol.105 (12), p.1-3761
Hauptverfasser:	Brar, Preneet Cheema, Heksch, Ryan, Cossen, Kristina, De Leon, Diva D, Kamboj, Manmohan K, Marks, Seth D, Marshall, Bess A, Miller, Ryan, Page, Laura, Stanley, Takara, Mitchell, Deborah, Thornton, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Child Child, Preschool Children Diazoxide Diazoxide - adverse effects Disease Management Diseases Dosage and administration Drug dosages Drug therapy Endocrinology Female Humans Hyperinsulinism - complications Hypoglycemia Hypoglycemia - drug therapy Hypoglycemia - etiology Infant Infants Insulin Antagonists - adverse effects Literature reviews Male Metabolic diseases Metabolic disorders in children Neonates Neutropenia Pediatrics Working groups
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!